Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case–control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.
Fusco, W., De Maio, F., Porcari, S., Severino, A., Salvi, D., Piccirelli, S., Ferrari, C., Sibilla, A., Quaranta, G., Masucci, L., Cammarota, G., Sanguinetti, M., Gasbarrini, A., Ianiro, G., Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic, <<NUTRIENTS>>, 2026; 18 (3): N/A-N/A. [doi:10.3390/nu18030490] [https://hdl.handle.net/10807/338241]
Informed Therapeutic Microbiome Modulation for Post-Infectious Irritable Bowel Syndrome: Pilot Experience of a Microbiome Clinic
Fusco, William;De Maio, Flavio;Porcari, Serena;Severino, Andrea;Salvi, Daniele;Ferrari, Clarissa;Sibilla, Antonio;Quaranta, Gianluca;Masucci, Luca;Cammarota, Giovanni;Sanguinetti, Maurizio;Gasbarrini, Antonio;Ianiro, Gianluca
2026
Abstract
Background: Untargeted microbiome modulation has achieved conflicting results in post-infectious irritable bowel syndrome (PI-IBS). Methods: In a case–control study of PI-IBS patients, cases received targeted microbial modulation informed by microbiome profiling, while controls were managed by standard therapy. Treatment response was defined as a decrease in IBS-symptom severity scale (IBS-SSS) ≥50 points. Results: All thirteen cases (100%) and 11/20 controls (55%) experienced treatment response (p < 0.0001). The mean IBS-SSS score after treatments was 163 in cases and 231 in controls (p = 0.01). Conclusions: Based on our preliminary results, therapeutic microbiome modulation might be a promising strategy for PI-IBS. Further studies are needed to clarify its role.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
